Roivant to present PHocus Phase 2 topline results for mosliciguat
Roivant and Pulmovant said results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease will be presented at ERS Congress 2026 on Tuesday, Sept. 8, 2026, plus an investor call.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.